Pharmacokinetics, Safety, And Tolerability Of Fevipiprant (Qaw039), A Novel Crth2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies In Healthy Volunteers (Vol 5, Pg 306, 2016)
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT(2020)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要